Cell therapy partnership aims to bring liver disease treatment closer to US patients
pharmafile | September 1, 2026 | News story | |Â Â Resolution Therapeutics, US, cell therapy, liver diseaseÂ
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery of its experimental cell therapy for end-stage liver disease, potentially widening access to treatment for patients who face barriers to travelling to specialist centres.
The partnership will support the pivotal clinical programme for RTX001, Resolution’s lead Regenerative Macrophage Therapy (RMT), which the company plans to begin in the US in 2027.
For patients with decompensated cirrhosis, liver transplantation is currently the only disease-modifying treatment option cited by Resolution. However, access to transplantation is limited by donor availability, proximity to transplant centres and the complexity and cost of surgery. Patients with advanced disease may also be too unwell to travel long distances for treatment.
Resolution says its approach is intended to address some of these practical barriers. RTX001 is a repeat-dose cell therapy administered through a peripheral IV, without pre-conditioning, bridging therapy or lymphodepletion. The company says early clinical studies have identified no significant safety signals or requirement for prolonged monitoring.
Under the partnership, BCA will be one of Resolution’s preferred providers of cell collection and processing services for pivotal-study sites requiring this support. Its network of independent blood centres provides a geographic footprint across the US, alongside expertise in apheresis, cell processing, handling and storage for autologous cell therapy programmes.
Amir Hefni, CEO of Resolution Therapeutics, said RTX001 had been designed and manufactured to overcome some of the historical limitations of administering cell therapies in community settings, allowing patients to receive treatment closer to home.
Bill Block, CEO of BCA, said the organisation’s national patient apheresis network and product-handling capabilities could support healthcare organisations in regions where cell therapy might otherwise be unavailable.
Resolution plans to finalise the pivotal study design and clinical-site selection following a pre-investigational new drug (IND) meeting with the US Food and Drug Administration.
Beyond RTX001, the company is developing RMT approaches for other inflammatory and fibrotic diseases, including lung fibrosis, alongside preclinical work on an in vivo RMT approach.
Related Content
Coriolis Pharma opens new US headquarter and laboratory
Coriolis Pharma has opened a new US headquarter and laboratory at the Alexandria Center for …
Abselion establishes a US subsidiary in MassachusettsÂ
Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US. …
ESTEVE CDMO commences $15.5m expansion of US facility
ESTEVE CDMO, a global Contract Development and Manufacturing Organization (CDMO) specialising in small molecule active pharmaceutical …
